The current research and clinical trials support three product lines the company is pursuing:

Individualized Cancer Immunotherapy System

This is our primary target product at this time. A complete description can be found in the Product Background portion of the web site. The vaccine is individually prepared for women already diagnosed with breast cancer. Blood drawn from a patient is treated with our patented process, and then cells are injected back into the patient in three doses, stimulating her own immune response.

Cancer Monitoring Test

This test uses some of the same patented technology as the Individualized Cancer Immunotherapy to monitor blood levels of the immune response in a patient following treatment. It can be used to monitor the remission process or done on a regular basis to ensure the vaccine stays effective. This is a simple blood draw, minimally invasive to the patient and very economical.

Cancer Screening Test

This test is an extension of the monitoring test and will require further clinical trials and documentation. However, the company is pursuing this product as a simple, affordable blood test, very much like the widely used PSA test. Further studies are needed to prove its reliability in breast cancer and possibly other types of cancer as well.